# Sitravatinib in Metastatic Breast Cancer

> **NCT04123704** · PHASE2 · TERMINATED · sponsor: **Xiang Zhang** · enrollment: 3 (actual)

## Conditions studied

- Breast Cancer Stage IV
- Triple Negative Breast Cancer
- Breast Neoplasms
- Breast Cancer Metastatic

## Interventions

- **DRUG:** Sitravatinib

## Key facts

- **NCT ID:** NCT04123704
- **Lead sponsor:** Xiang Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-22
- **Primary completion:** 2023-01-22
- **Final completion:** 2023-01-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Terminated by sponsor due to lack of interest
- **Last updated:** 2024-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04123704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04123704, "Sitravatinib in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04123704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*